ADTX Stock Summary and Trading Ideas (Aditxt | NASDAQ:ADTX)

Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues.

Aditxt trades on the NASDAQ stock market under the symbol ADTX.

As of December 19, 2025, ADTX stock price declined to $1.16 with 466,374 million shares trading.

ADTX has a beta of 1.59, meaning it tends to be more sensitive to market movements. ADTX has a correlation of 0.02 to the broad based SPY ETF.

ADTX has a market cap of $2.07 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, ADTX traded as high as $86,332,000.00 and as low as $1.13.

ADTX has underperformed the market in the last year with a price return of -100.0% while the SPY ETF gained +18.1%. ADTX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -98.9% and -62.2%, respectively, while the SPY returned +2.8% and -0.5%, respectively.

ADTX support price is $1.03 and resistance is $1.49 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ADTX shares will trade within this expected range on the day.